Dyne Therapeutics, Inc. (DYN) Research

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Market snapshot

Symbol
DYN
Price
$19.80
Day change
+3.13%
Market cap
$3.3B
P/E ratio
-7.23x
52-week range
8.06-25
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$35.50

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Apogee Therapeutics, Inc. (APGE)
  • Celcuity Inc. (CELC)
  • CG Oncology, Inc. Common stock (CGON)
  • Centessa Pharmaceuticals plc (CNTA)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Soleno Therapeutics, Inc. (SLNO)

Recent insider activity

  • Kerr Douglas — S-Sale (887 shares) on 2026-06-16
  • Friedl-Naderer Johanna — S-Sale (145 shares) on 2026-06-16
  • Cox John — S-Sale (2683 shares) on 2026-06-16
  • HURWITZ EDWARD — A-Award (35152 shares) on 2026-06-05
  • Lubner David Charles — A-Award (35152 shares) on 2026-06-05

Open Dyne Therapeutics, Inc. (DYN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.